62 results
8-K/A
EX-99.3
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
is directly linked with the initiation of the neurodegenerative process through synaptic dysfunction. Our technology targets the molecular mechanisms within … University Langone Medical Center, we have demonstrated that neflamapimod specifically targets the specific molecular mechanisms underlying basal forebrain
424B3
CRVO
CervoMed Inc
13 Jul 23
Prospectus supplement
4:32pm
to TSC and had the potential to diversify and reduce the perceived risk profile of Diffusion’s asset portfolio as targets for an acquisition
S-4/A
jqkw98otytld1lfa4
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
8gi9is 43k
10 May 23
Registration of securities issued in business combination transactions
9:56pm
424B3
pa2fjl tt7
8 Jun 20
Prospectus supplement
4:48pm
424B5
icirc7jl760z8elkoewx
19 May 20
Prospectus supplement for primary offering
5:29pm
424B3
zxlaahdfe1mgjttxa
30 Dec 19
Prospectus supplement
10:07am
424B5
ruqfrcdyi1pquixy0wqf
13 Dec 19
Prospectus supplement for primary offering
7:59am
424B4
3rw gd9s3f
15 Nov 19
Prospectus supplement with pricing info
12:00am